Tenaya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
06/08/2025 23:38
Tenaya Therapeutics Inc TNYA.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of nine analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -71 cents to -11 cents per share. Reported revenue was zero; analysts expected zero. Tenaya Therapeutics Inc's reported EPS for the quarter was a loss of 14 cents. The company reported a quarterly loss of $23.28 million. Tenaya Therapeutics Inc shares had risen by 13.8% this quarter and lost 51.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 48% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $5.00, about 86.5% above its last closing price of $0.67 This summary was machine generated from LSEG data August 6 at 10:38 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.25 | -0.14 | Beat |
| Mar. 31 2025 | -0.19 | -0.24 | Missed |
| Dec. 31 2024 | -0.31 | -0.28 | Beat |
| Sep. 30 2024 | -0.37 | -0.30 | Beat |
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027